NovoCure (NVCR) Q4 2023 Earnings Call Transcript
NVCR earnings call for the period ending December 31, 2023.
Stay updated with breaking news from Jonathan Chang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NVCR earnings call for the period ending December 31, 2023.
NVCR earnings call for the period ending December 31, 2023.
Board members have reaped hundreds of millions from stock awards and separate investments, even as some have done drugs with Musk; former Tesla director Larry Ellison offered him a chance to dry out.
Johnson & Johnson’s acquisition of antibody drug conjugate developer Ambrx Biopharma comes as Novartis and Merck also unveiled M&A deals on the first day of the J.P. Morgan Healthcare conference. In a report, the investment bank said big pharmas are looking for deals involving de-risked assets.
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.